rosiglitazone has been researched along with montelukast in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 10 (66.67) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Gaman, EA; Gleeson, JP; Obach, RS; Proctor, WR; Walsky, RL | 1 |
| Kim, KA; Kim, KR; Park, JY; Park, PW | 1 |
| Foti, RS; Rock, DA; VandenBrink, BM; Wahlstrom, JL; Wienkers, LC | 1 |
| Korzekwa, K | 2 |
| Hosaka, S; Iwano, S; Iwasaki, K; Murayama, N; Satsukawa, M; Shimizu, M; Uehara, S; Uno, Y; Yamazaki, H | 1 |
1 review(s) available for rosiglitazone and montelukast
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for rosiglitazone and montelukast
| Article | Year |
|---|---|
Effect of multiple doses of montelukast on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in humans.
Topics: Acetates; Adult; Cross-Over Studies; Cyclopropanes; Drug Interactions; Humans; Hypoglycemic Agents; Leukotriene Antagonists; Male; Quinolines; Rosiglitazone; Sulfides; Thiazolidinediones | 2007 |
13 other study(ies) available for rosiglitazone and montelukast
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
Selective inhibition of human cytochrome P4502C8 by montelukast.
Topics: Acetates; Amodiaquine; Anti-Asthmatic Agents; Aryl Hydrocarbon Hydroxylases; Cyclopropanes; Cytochrome P-450 CYP2C8; Drug Interactions; Enzyme Inhibitors; Humans; In Vitro Techniques; Leukotriene Antagonists; Microsomes, Liver; Paclitaxel; Quinolines; Recombinant Proteins; Rosiglitazone; Sulfides; Thiazolidinediones | 2005 |
Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate.
Topics: Acetates; Amodiaquine; Aryl Hydrocarbon Hydroxylases; Binding Sites; Carbamates; Cyclopropanes; Cytochrome P-450 CYP2C8; Drug Interactions; Humans; Microsomes, Liver; Paclitaxel; Piperidines; Quinolines; Rosiglitazone; Sensitivity and Specificity; Substrate Specificity; Sulfides; Thiazolidinediones | 2011 |
Case study 4. Predicting the drug interaction potential for inhibition of CYP2C8 by montelukast.
Topics: Acetates; Aryl Hydrocarbon Hydroxylases; Cyclopropanes; Cytochrome P-450 CYP2C8; Drug Interactions; Enzyme Assays; Enzyme Inhibitors; Hepatocytes; Humans; Intracellular Space; Quinolines; Rosiglitazone; Sulfides; Thiazolidinediones | 2014 |
Identification of putative substrates for cynomolgus monkey cytochrome P450 2C8 by substrate depletion assays with 22 human P450 substrates and inhibitors.
Topics: Acetates; Amodiaquine; Animals; Cyclopropanes; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Macaca fascicularis; Pharmaceutical Preparations; Quercetin; Quinolines; Rosiglitazone; Species Specificity; Substrate Specificity; Sulfides; Thiazolidinediones | 2016 |
Case Study 5: Predicting the Drug Interaction Potential for Inhibition of CYP2C8 by Montelukast.
Topics: Acetates; Area Under Curve; Cyclopropanes; Cytochrome P-450 CYP2C8; Drug Interactions; Humans; Kinetics; Plasma; Quinolines; Rosiglitazone; Sulfides | 2021 |